Generic Femilon ( Estrogen and Progesterone )

Buy Generic Femilon (Estrogen and Progesterone) without prescription in Canada

In our Canadian pharmacy, you can buy Femilon (Desogestrel / Ethinyl Estradiol) without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Femilon is a low‑dose combined hormonal oral contraceptive containing the progestin desogestrel and the estrogen ethinyl estradiol. It works primarily by preventing the release of an egg from the ovary (ovulation), and it also thickens the cervical mucus to make it harder for sperm to reach the uterus, while thinning the uterine lining to reduce the likelihood of implantation. Desogestrel is a third‑generation progestin with minimal androgenic activity, which helps to reduce the risk of acne and unwanted hair growth, and ethinyl estradiol provides reliable cycle control. The very low estrogen dose (0.02 mg) is designed to maintain contraceptive efficacy while minimising estrogen‑related side effects such as nausea, breast tenderness, and bloating.

Usual adult dose: One active tablet is taken orally once daily, at approximately the same time each day, for 21 consecutive days, followed by a 7‑day tablet‑free interval during which withdrawal bleeding usually occurs. Each active tablet contains 0.15 mg of desogestrel and 0.02 mg of ethinyl estradiol. The next pack is started on the day after the tablet‑free interval, regardless of whether bleeding has stopped. Contraceptive protection is maintained throughout the cycle provided tablets are taken correctly. If the first tablet is taken on the first day of menstrual bleeding (Day 1 start), no backup contraception is needed; otherwise, a barrier method must be used for the first 7 days.

Dosage form: Oral tablets, each containing desogestrel 0.15 mg and ethinyl estradiol 0.02 mg, supplied in 21‑day blister packs.

Onset of action: Contraceptive protection begins immediately if the first tablet is taken on the first day of menstrual bleeding. If started at any other time in the cycle, a backup barrier method must be used for the first 7 days.

Duration of action: Contraceptive protection is maintained throughout the entire 28‑day cycle (21 active tablets + 7‑day break) as long as tablets are taken correctly and without interruption. The hormone‑free interval does not reduce protection when the next pack is started on time.

Alcohol recommendation: Moderate alcohol consumption does not directly interfere with the contraceptive action of Femilon, but excessive drinking may increase the risk of vomiting or severe diarrhoea, which can impair tablet absorption. Alcohol should be limited, and a backup contraceptive method should be considered if vomiting occurs within 3‑4 hours of taking an active tablet.

Most common side effects: Irregular uterine bleeding (spotting or breakthrough bleeding, especially during the first few months), nausea, breast tenderness, headache, mood changes, and weight changes. Nausea often improves when the tablet is taken with food or at bedtime. Desogestrel‑containing pills are associated with a low rate of acne and hirsutism due to the weak androgenic profile of the progestin. Rare but serious side effects include an increased risk of venous thromboembolism (blood clots).

Would you like to try Femilon (Desogestrel / Ethinyl Estradiol) without a prescription?

General Information about Femilon (Desogestrel / Ethinyl Estradiol)

• INN (International Nonproprietary Name): Desogestrel and Ethinyl Estradiol
• Brand names available in Canada: Femilon® is not a marketed brand in Canada. The combination of desogestrel and ethinyl estradiol is available in Canada under other brand names such as Marvelon® (0.15 mg/0.03 mg) and others, but the specific 0.15 mg/0.02 mg low‑estrogen formulation is not approved by Health Canada. Femilon is an internationally sourced product obtained by our pharmacy through the international supply chain for personal importation.
• ATC code: G03AA09 (desogestrel and ethinyl estradiol; fixed combinations).
• Dosage forms and strengths: Oral tablets, each containing 0.15 mg desogestrel and 0.02 mg ethinyl estradiol, supplied in blister packs of 21 active tablets.
• Manufacturers in Canada: None. Femilon is not manufactured in Canada. It is produced internationally by various pharmaceutical companies; the product is obtained via the international supply chain for personal use.
• Registration status in Canada: Not marketed in Canada. Femilon has not been issued a Notice of Compliance by Health Canada and is not listed in the Drug Product Database. The active combination is approved in different strengths only.
• OTC / Rx classification: Prescription only (Rx). A valid prescription from a licensed Canadian healthcare professional is required for personal importation. The product is supplied as an oral contraceptive and is not available over the counter.

Mechanism of Action and Pharmacology

Femilon is a monophasic combined oral contraceptive. The contraceptive effect is achieved primarily through the inhibition of ovulation: the exogenous estrogen (ethinyl estradiol) and progestin (desogestrel) suppress the mid‑cycle surge of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), thereby preventing the maturation and release of an ovum. Desogestrel is a highly selective progestin derived from levonorgestrel; it is a prodrug that is rapidly converted in the body to its active metabolite, 3‑keto‑desogestrel (etonogestrel). It has strong progestational and anti‑ovulatory activity with minimal androgenic effects. Ethinyl estradiol provides the estrogenic component necessary for cycle control and endometrial stability. Secondary contraceptive mechanisms include the progestin‑induced thickening of the cervical mucus, which hinders sperm penetration, and alteration of the endometrial lining, which becomes less receptive to implantation.

After oral administration, both components are rapidly absorbed, with peak plasma concentrations reached within 1‑2 hours. Desogestrel is extensively metabolised in the liver and gastrointestinal wall to etonogestrel, which is highly bound to sex‑hormone‑binding globulin (SHBG). Ethinyl estradiol is bound to albumin and induces an increase in SHBG. The elimination half‑life of etonogestrel is approximately 30 hours, and that of ethinyl estradiol is approximately 10‑20 hours. Steady‑state concentrations are achieved within 3‑5 days of daily administration. The low estrogen dose (0.02 mg) compared with older formulations (0.03‑0.05 mg) reduces estrogen‑related side effects while maintaining contraceptive efficacy.

Indications

• Prevention of pregnancy in women who elect to use an oral contraceptive. Femilon is a low‑dose formulation particularly suited for women who are sensitive to higher doses of estrogen or who experience estrogen‑related side effects such as nausea, breast tenderness, or bloating.
• May also be used for the regulation of menstrual cycles in women with irregular menses, and off‑label for the management of mild to moderate acne and hirsutism due to the anti‑androgenic properties of desogestrel (note: official approval for acne may require a different formulation in Canada).
• Femilon is intended for women of reproductive age. It is not indicated for postmenopausal women, children before menarche, or men.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Femilon is contraindicated during pregnancy. If pregnancy occurs, the medication must be discontinued immediately. There is no evidence of an increased risk of birth defects in women who inadvertently used combined oral contraceptives early in pregnancy.
• Breastfeeding: Combined hormonal contraceptives may reduce milk production and affect the composition of breast milk. Small amounts of contraceptive steroids are excreted in breast milk. Femilon is not recommended during breastfeeding; a progestin‑only contraceptive is generally preferred.
• Paediatrics (< menarche): Safety and efficacy have not been established in children or adolescents before menarche. Femilon is indicated only for women of reproductive age.
• Elderly: Femilon is not indicated for use in postmenopausal women and should not be used as hormone replacement therapy.
• Venous thromboembolism (VTE): All combined oral contraceptives increase the risk of deep vein thrombosis and pulmonary embolism. The risk is highest during the first year of use and in women with a personal or family history of VTE, thrombophilia, obesity, or prolonged immobilisation. The risk with desogestrel‑containing pills is slightly higher than with levonorgestrel‑containing pills, but the absolute risk remains low. The very low estrogen dose (0.02 mg) may mitigate some of the VTE risk compared with higher‑dose formulations, but careful patient selection is required.
• Arterial thromboembolism: The risk of myocardial infarction and stroke is increased in users of combined oral contraceptives, particularly in women who smoke, are over 35 years of age, have hypertension, or have migraine with aura. Femilon should be discontinued at least 4 weeks before major elective surgery and during prolonged immobilisation.
• Hypertension: Femilon is contraindicated in women with uncontrolled hypertension. Blood pressure should be checked before starting therapy and monitored periodically.
• Liver disease: Femilon is contraindicated in women with active liver disease, including viral hepatitis, cirrhosis, or liver tumours (benign or malignant). Liver function must return to normal before the medication can be used.
• Migraine: Combined oral contraceptives are contraindicated in women with migraine with aura (focal neurological symptoms). In women who develop new‑onset migraine or significant worsening of migraines, the medication should be discontinued.
• Diabetes mellitus: Low‑dose combined oral contraceptives have a small effect on glucose and lipid metabolism. Women with diabetes should be monitored carefully, and their insulin or oral hypoglycaemic requirements may need adjustment.
• Breast and reproductive cancers: Long‑term use of combined oral contraceptives is associated with a slight increase in the risk of breast and cervical cancer. Femilon is contraindicated in women with known or suspected breast carcinoma or other estrogen‑ or progestin‑dependent neoplasia.
• Gallbladder disease: Combined oral contraceptives increase the risk of gallstone formation and cholecystitis.
• Depression: Women with a history of depression should be observed carefully, and the drug should be discontinued if severe depression recurs.
• Allergy: Do not take Femilon if you have a known hypersensitivity to desogestrel, ethinyl estradiol, or any excipient in the tablet.

Driving and alcohol

Femilon has no known influence on the ability to drive or operate machinery. Moderate alcohol consumption does not directly interfere with the contraceptive effect; however, excessive drinking can lead to vomiting or severe diarrhoea, which may reduce the absorption of the active tablets. Women who vomit within 3‑4 hours of taking an active tablet should use a backup contraceptive method. Alcohol intake should be limited to minimise the risk of gastrointestinal upset that could compromise contraceptive reliability.

Dosage Instructions

• Standard regimen: Take one tablet daily at approximately the same time each day for 21 consecutive days, followed by a 7‑day tablet‑free interval. Withdrawal bleeding usually begins 2‑3 days after the last active tablet. A new pack is started on the day after the tablet‑free interval, regardless of whether bleeding has stopped.
• Starting Femilon:
  • Day 1 start: Take the first tablet on the first day of menstrual bleeding. Contraceptive protection begins immediately; no backup method is needed.
  • Sunday start: Take the first tablet on the first Sunday after the onset of menstrual bleeding. A backup barrier method (e.g., condoms) must be used for the first 7 days.
  • Switching from another combined hormonal contraceptive: Start Femilon on the day after the last active tablet of the previous product. No backup method is required.
  • After childbirth or second‑trimester abortion: Start no earlier than 4 weeks postpartum (6 weeks if breastfeeding is being considered). If intercourse has already occurred, pregnancy must be excluded before starting.
  • After first‑trimester abortion: Femilon can be started immediately.
• Missed tablet(s):
  • If one active tablet is missed by less than 24 hours, take it as soon as remembered and continue taking the remaining tablets at the usual time. No backup method is needed.
  • If two consecutive active tablets are missed in week 1 or week 2, take two tablets on the day remembered and two tablets the next day, then continue with one tablet daily. Use a backup method for 7 days.
  • If two consecutive active tablets are missed in week 3, or three or more active tablets are missed at any time: discard the rest of the pack and start a new pack that same day. Use a backup method for 7 days.
• Gastrointestinal upset: If vomiting or severe diarrhoea occurs within 3‑4 hours of taking an active tablet, treat this as a missed tablet and follow the missed‑tablet instructions. Use a backup method for 7 days.
• Withdrawal bleeding: The absence of a withdrawal period during the tablet‑free interval may indicate pregnancy. Pregnancy should be excluded before starting the next pack if two consecutive cycles have no withdrawal bleeding.

Side Effects and Contraindications

• Common side effects (≥ 1%): Irregular uterine bleeding (spotting or breakthrough bleeding, especially in early cycles), nausea, breast tenderness, headache, mood changes (including depression and irritability), weight changes, decreased libido, and vaginal candidiasis. The low estrogen dose of 0.02 mg reduces the incidence and severity of nausea and breast tenderness compared with higher‑dose pills, but may be associated with a slightly higher rate of breakthrough bleeding in some women.
• Serious adverse reactions: Venous thromboembolism (deep vein thrombosis, pulmonary embolism), arterial thromboembolism (myocardial infarction, stroke, retinal thrombosis), hypertension, gallbladder disease, benign and malignant liver tumours (including hepatocellular carcinoma and hepatic adenoma), pancreatitis associated with severe hypertriglyceridemia, and chloasma (melasma) that may be permanent. An increased risk of breast and cervical cancer has been observed in long‑term users.
• Desogestrel‑specific effects: Desogestrel is associated with a slightly higher relative risk of VTE compared with levonorgestrel, though the absolute risk is low. The low estrogen dose may partially offset this risk. Desogestrel is otherwise well tolerated with a favourable androgenic profile, minimising acne and hirsutism.
• Contraindications: History of or current venous thromboembolism or thrombophlebitis; known thrombophilic conditions; history of or current arterial thromboembolism (myocardial infarction, stroke, transient ischaemic attack); migraine with aura or focal neurological symptoms; diabetes mellitus with vascular involvement; uncontrolled hypertension; known or suspected estrogen‑ or progestin‑dependent neoplasia (including breast carcinoma); active liver disease or history of liver tumours (benign or malignant); undiagnosed abnormal genital bleeding; known or suspected pregnancy; hypersensitivity to any component of the product.

Drug Interactions

• Enzyme‑inducing drugs (reduce contraceptive efficacy): Rifampin, rifabutin, carbamazepine, phenobarbital, phenytoin, primidone, oxcarbazepine, topiramate, felbamate, griseofulvin, and products containing St. John's wort may increase hepatic metabolism of contraceptive hormones, leading to breakthrough bleeding or unintended pregnancy. A backup barrier method should be used while taking these inducers and for 28 days after discontinuation.
• Protease inhibitors and NNRTIs: Some HIV protease inhibitors (e.g., ritonavir, nelfinavir) and non‑nucleoside reverse transcriptase inhibitors (e.g., nevirapine, efavirenz) can alter contraceptive steroid metabolism, potentially reducing efficacy. A condom should be used in addition to Femilon.
• Antibiotics (controversial interaction): With the exception of rifampin‑like drugs, most antibiotics (e.g., ampicillin, tetracyclines) have not been consistently shown to reduce the effectiveness of oral contraceptives. No routine backup method is recommended, but women who experience breakthrough bleeding during antibiotic therapy may choose to use additional protection.
• Lamotrigine: Ethinyl estradiol may reduce plasma concentrations of lamotrigine, potentially reducing seizure control or requiring a dose adjustment.
• Cyclosporine, theophylline, and corticosteroids: Estrogen‑containing contraceptives may inhibit the metabolism of cyclosporine, increase concentrations of theophylline, and prolong the half‑life of corticosteroids (e.g., prednisolone). Appropriate dose adjustments and monitoring are advised.

Practical Advice

• Administration: Take one tablet every day at the same time, without skipping days. Tablets may be taken with or without food; taking with a meal or at bedtime may reduce nausea. If you have difficulty remembering, set a daily alarm or link tablet‑taking to a routine activity.
• Monitoring: Before starting Femilon, a complete medical history and physical examination should be performed, including a blood pressure check, breast and pelvic examination, and assessment of risk factors for thromboembolism. Blood pressure should be rechecked periodically. Women over 35 who smoke should be counselled strongly to stop smoking, as the cardiovascular risks are substantially elevated.
• Storage: Store at room temperature (15‑30 °C) in the original packaging, protected from moisture and light. Keep out of the reach and sight of children.
• Lifestyle: Femilon does not protect against HIV/AIDS or other sexually transmitted infections. A condom should be used for STI protection. If you plan to become pregnant, discontinue Femilon and wait for one spontaneous menstrual period before trying to conceive. If you are scheduled for major surgery or prolonged immobilisation, inform your surgeon that you are taking an oral contraceptive; the pill may need to be stopped 4 weeks beforehand.
• When to seek medical attention: Stop taking Femilon and contact your doctor immediately if you experience any of the following warning signs of a blood clot: sudden severe chest pain or shortness of breath, coughing up blood, unexplained swelling or pain in a leg, sudden severe headache or vomiting, dizziness or fainting, weakness or numbness of the face, arm, or leg, vision loss or double vision, or jaundice (yellowing of the skin or eyes).
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Other low‑dose combined oral contraceptives (COCs) available in Canada: Aviane®, Lutera®, and Portia® contain levonorgestrel 0.10 mg and ethinyl estradiol 0.02 mg, providing a similar very low estrogen dose with a different progestin. Marvelon® contains desogestrel 0.15 mg and ethinyl estradiol 0.03 mg, offering a higher estrogen dose for women who experience breakthrough bleeding on 0.02 mg estrogen pills.
• Progestin‑only contraceptives: The “mini‑pill” (norethindrone or levonorgestrel), the depot‑medroxyprogesterone acetate injection (Depo‑Provera), the etonogestrel implant (Nexplanon), and the levonorgestrel‑releasing intrauterine system (Mirena, Kyleena, Jaydess) are alternatives for women who cannot take estrogen.
• Non‑hormonal options: Copper intrauterine devices (e.g., Nova‑T, Flexi‑T) provide long‑acting, hormone‑free contraception. Barrier methods (male and female condoms, diaphragms) offer STI protection but have higher pregnancy rates with typical use.

Clinical Efficacy

The contraceptive efficacy of desogestrel 0.15 mg/ethinyl estradiol 0.02 mg is well documented. With perfect use, the Pearl Index is approximately 0.1‑0.4 pregnancies per 100 woman‑years. With typical use, the Pearl Index rises to approximately 9. The 0.02 mg ethinyl estradiol formulation provides reliable ovulation inhibition while minimising estrogen‑related side effects. Clinical studies have shown that this low‑dose combination offers effective cycle control with a low incidence of breakthrough bleeding and spotting, comparable to higher‑dose formulations. The desogestrel component provides good acne control and is associated with favourable effects on lipid profiles, including increased high‑density lipoprotein (HDL) cholesterol. The VTE risk associated with desogestrel‑containing pills is slightly elevated compared with levonorgestrel‑containing pills, but remains low in absolute terms for healthy, non‑smoking women under 35. International guidelines support the use of low‑dose combined oral contraceptives as a first‑line contraceptive option for most women.

Important:

Femilon (desogestrel/ethinyl estradiol) is a prescription combined hormonal contraceptive that should be used only under the supervision of a qualified healthcare professional. It is not to be used during pregnancy or while breastfeeding. Cigarette smoking, particularly in women over 35 years of age, greatly increases the risk of serious cardiovascular events, including heart attack, stroke, and blood clots. Femilon is contraindicated in women with a history of venous thromboembolism, thrombophilia, migraine with aura, uncontrolled hypertension, liver disease, or estrogen‑dependent cancers. This product is not approved by Health Canada and is imported for personal use under a valid prescription. Seek emergency medical attention immediately if you develop symptoms of a blood clot, such as sudden severe chest pain, shortness of breath, coughing up blood, unexplained leg pain or swelling, sudden severe headache or weakness on one side of the body. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Femilon - Shipping across Canada